Premium
Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer
Author(s) -
Nakamura Tatsuya,
Fuwa Nobukazu,
Takayama Kanako,
Inokuchi Haruo,
Tomoda Takuya,
Takada Akinori,
Makita Chiyoko,
Shiomi Miho,
Yokouchi Jun–ichi,
Watanabe Kazuo
Publication year - 2012
Publication title -
head and neck
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.012
H-Index - 127
eISSN - 1097-0347
pISSN - 1043-3074
DOI - 10.1002/hed.21983
Subject(s) - docetaxel , medicine , leukopenia , head and neck cancer , cisplatin , regimen , toxicity , chemotherapy , cancer , limiting , anesthesia , oncology , urology , mechanical engineering , engineering
Background We planned a phase I study of weekly arterial infusion of docetaxel and cisplatin via a superficial temporal artery for recurrent head and neck cancer to determine the optimal dose. Methods The dose of cisplatin was fixed and the dose of docetaxel was escalated from 8 mg/m 2 , with an increase of 2 mg/m 2 per step, to identify the maximum tolerated dose (MTD). In total, 4 courses of weekly chemotherapy were administered. Results Twelve patients were recruited to this trial. The MTD of docetaxel was 14 mg/m 2 . At this dose level, dose‐limiting toxicity was observed in 2 of 3 patients. One patient experienced grade 3 leukopenia, while the other experienced grade 3 leukopenia. Myelosuppression was the dose‐limiting toxicity for this regimen. Conclusion The recommended dose for weekly arterial infusion of docetaxel was identified as 12 mg/m 2 combined with weekly cisplatin at 40 mg/m 2 , with 4 courses of each. © 2011 Wiley Periodicals, Inc. Head Neck , 2011